omeprazole has been researched along with Duodenal Reflux in 12 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both sucralfate and rabeprazole therapies are effective treatment options in the patients with alkaline gastritis when compared with observation." | 9.10 | Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. ( Cammarota, G; Candelli, M; Cremonini, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Santarelli, L, 2003) |
| "The GABA(B) receptor agonist baclofen improves duodenal reflux and associated reflux symptoms that persist during PPI therapy." | 9.10 | Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. ( Janssens, J; Koek, GH; Lerut, T; Sifrim, D; Tack, J, 2003) |
| " However, little is known about the effect of omeprazole on duodenogastric reflux (DGR) and duodenogastro-oesophageal reflux (DGOR)." | 9.08 | Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. ( Anggiansah, A; Manifold, DK; Marshall, RE; Owen, WA; Owen, WJ, 1998) |
| "Gastric secretion was measured in nine patients with duodenal ulcer before, and after treatment for four weeks with omeprazole 20 mg or 40 mg daily." | 7.67 | Basal, sham feed and pentagastrin stimulated gastric acid, pepsin and electrolytes after omeprazole 20 mg and 40 mg daily. ( Baron, JH; Barr, JA; Bush, A; Collier, N; Cope, L; Gribble, RJ; Spencer, J; Thompson, JN, 1985) |
| "Both sucralfate and rabeprazole therapies are effective treatment options in the patients with alkaline gastritis when compared with observation." | 5.10 | Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. ( Cammarota, G; Candelli, M; Cremonini, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Santarelli, L, 2003) |
| "The GABA(B) receptor agonist baclofen improves duodenal reflux and associated reflux symptoms that persist during PPI therapy." | 5.10 | Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. ( Janssens, J; Koek, GH; Lerut, T; Sifrim, D; Tack, J, 2003) |
| " However, little is known about the effect of omeprazole on duodenogastric reflux (DGR) and duodenogastro-oesophageal reflux (DGOR)." | 5.08 | Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. ( Anggiansah, A; Manifold, DK; Marshall, RE; Owen, WA; Owen, WJ, 1998) |
| "Gastric secretion was measured in nine patients with duodenal ulcer before, and after treatment for four weeks with omeprazole 20 mg or 40 mg daily." | 3.67 | Basal, sham feed and pentagastrin stimulated gastric acid, pepsin and electrolytes after omeprazole 20 mg and 40 mg daily. ( Baron, JH; Barr, JA; Bush, A; Collier, N; Cope, L; Gribble, RJ; Spencer, J; Thompson, JN, 1985) |
| "However, recent work suggests that duodenogastric reflux (DGR) may be reduced by omeprazole." | 2.69 | Effect of omeprazole on antral duodenogastric reflux in Barrett oesophagus. ( Anggiansah, A; Manifold, DK; Marshall, RE; Owen, WJ, 2000) |
| "Studying role of duodenogastric reflux (DGR) in pathogenesis and sanogenesis of duodenal ulcer (DU)." | 1.37 | [Characteristics of duodenogastric reflux in duodenal ulcer patients and its dynamics after Helicobacter pylori eradication]. ( Kolesnikova, IIu; Liubskaia, LA; Volkov, VS, 2011) |
| "Gastroesophageal reflux disease patients who continued to report symptoms 3 times a week for 3 months while on PPI once a day were assigned to the PPI failure group." | 1.35 | Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. ( Fass, R; Gasiorowska, A; Koenig, K; Krupinski, E; Moty, B; Navarro-Rodriguez, T; Perry, ZH; Powers, J; Wendel, C, 2009) |
| "Duodenogastric reflux is known to cause an increased frequency of cancer in the glandular portion of the stomach in rats." | 1.32 | Lanzoprazole promotes gastric carcinogenesis in rats with duodenogastric reflux. ( Maartmann-Moe, H; Viste, A; Waldum, H; Øvrebø, K, 2004) |
| "None of the rats developed esophageal cancer, but esophageal mucosal hyperplasia was more pronounced in rats receiving omeprazole." | 1.30 | Gastric acid blockade with omeprazole promotes gastric carcinogenesis induced by duodenogastric reflux. ( Adrian, TE; Hinder, RA; Perdikis, G; Profanter, C; Smyrk, T; Wetscher, GJ, 1999) |
| "We investigated whether duodenogastric reflux (DGR) together with gastroesophageal reflux causes growth stimulation of the foregut mucosa and if additional gastric acid suppression enhances the effect of DGR." | 1.29 | Duodenogastric reflux causes growth stimulation of foregut mucosa potentiated by gastric acid blockade. ( Adrian, TE; Hinder, RA; Klingler, PJ; Kretchmar, D; Perdikis, G; Smyrk, T; Stinson, R; Wetscher, GJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Monteiro, RLR | 1 |
| Kobayasi, MAMR | 1 |
| Araujo, MR | 1 |
| Monteiro, DR | 1 |
| Andreollo, NA | 1 |
| Gasiorowska, A | 1 |
| Navarro-Rodriguez, T | 1 |
| Wendel, C | 1 |
| Krupinski, E | 1 |
| Perry, ZH | 1 |
| Koenig, K | 1 |
| Moty, B | 1 |
| Powers, J | 1 |
| Fass, R | 1 |
| Kolesnikova, IIu | 1 |
| Volkov, VS | 1 |
| Liubskaia, LA | 1 |
| Santarelli, L | 1 |
| Gabrielli, M | 1 |
| Candelli, M | 1 |
| Cremonini, F | 1 |
| Nista, EC | 1 |
| Cammarota, G | 1 |
| Gasbarrini, G | 1 |
| Gasbarrini, A | 1 |
| Koek, GH | 1 |
| Sifrim, D | 1 |
| Lerut, T | 1 |
| Janssens, J | 1 |
| Tack, J | 1 |
| Viste, A | 1 |
| Øvrebø, K | 1 |
| Maartmann-Moe, H | 1 |
| Waldum, H | 1 |
| Wetscher, GJ | 2 |
| Hinder, RA | 2 |
| Kretchmar, D | 1 |
| Stinson, R | 1 |
| Perdikis, G | 2 |
| Smyrk, T | 2 |
| Klingler, PJ | 1 |
| Adrian, TE | 2 |
| Waring, JP | 1 |
| Hunter, JG | 1 |
| Marshall, RE | 2 |
| Anggiansah, A | 2 |
| Manifold, DK | 2 |
| Owen, WA | 1 |
| Owen, WJ | 2 |
| Profanter, C | 1 |
| Thompson, JN | 1 |
| Barr, JA | 1 |
| Collier, N | 1 |
| Spencer, J | 1 |
| Bush, A | 1 |
| Cope, L | 1 |
| Gribble, RJ | 1 |
| Baron, JH | 1 |
4 trials available for omeprazole and Duodenal Reflux
| Article | Year |
|---|---|
Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Benzi | 2003 |
Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.
Topics: Adult; Baclofen; Chi-Square Distribution; Drug Resistance; Drug Therapy, Combination; Duodenogastric | 2003 |
Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophagus; Bile Reflux; Bilirubin; Drug A | 1998 |
Effect of omeprazole on antral duodenogastric reflux in Barrett oesophagus.
Topics: Adolescent; Adult; Aged; Barrett Esophagus; Bilirubin; Duodenogastric Reflux; Endoscopy, Gastrointes | 2000 |
8 other studies available for omeprazole and Duodenal Reflux
| Article | Year |
|---|---|
Omeprazole and adenocarcinoma in the stomach of rats submitted to duodenogastric reflux. Is there a protective effect?
Topics: Adenocarcinoma; Animals; Duodenogastric Reflux; Gastric Mucosa; Humans; Omeprazole; Proton Pump Inhi | 2020 |
Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Duodenogastric Reflux; Esophageal pH M | 2009 |
[Characteristics of duodenogastric reflux in duodenal ulcer patients and its dynamics after Helicobacter pylori eradication].
Topics: Adult; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenogastric Reflux | 2011 |
Lanzoprazole promotes gastric carcinogenesis in rats with duodenogastric reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Administration, Oral; Animals; Duodenogastr | 2004 |
Duodenogastric reflux causes growth stimulation of foregut mucosa potentiated by gastric acid blockade.
Topics: Animals; DNA; Duodenogastric Reflux; Esophagus; Gastric Acid; Gastric Acidity Determination; Gastric | 1996 |
Patients failing moderately high doses of omeprazole.
Topics: Anti-Ulcer Agents; Duodenogastric Reflux; Humans; Laparoscopy; Omeprazole; Proton Pump Inhibitors; T | 1997 |
Gastric acid blockade with omeprazole promotes gastric carcinogenesis induced by duodenogastric reflux.
Topics: Adenocarcinoma; Animals; Anti-Ulcer Agents; Disease Models, Animal; Duodenogastric Reflux; Esophagea | 1999 |
Basal, sham feed and pentagastrin stimulated gastric acid, pepsin and electrolytes after omeprazole 20 mg and 40 mg daily.
Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Duodenogastric Reflux; Electrolytes; Feedi | 1985 |